Tag Archives: Treatment

Veterans benefit from pain treatment without drugs

A new study finds a lower risk of adverse post-treatment outcomes among returning military service personnel with chronic pain who received nondrug therapy. Share on PinterestNew research shows that some nondrug therapies, including exercise therapy, can help relieve pain in veterans. Many people returning from military deployment experience physical and mental health issues. These can… Read More »

FDA Approves Monoferric (ferric derisomaltose) Injection for the Treatment of Iron Deficiency Anemia

FDA Approves Monoferric (ferric derisomaltose) Injection for the Treatment of Iron Deficiency Anemia Print this page MORRISTOWN, N.J., Jan. 29, 2020 /PRNewswire/ — Pharmacosmos Therapeutics Inc. is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved Monoferric® (ferric derisomaltose) injection 100 mg/mL.  Monoferric® is an intravenous iron indicated for the treatment of iron… Read More »

Lynparza (olaparib) Approved in the US as a First-Line Maintenance Treatment of Germline BRCA-Mutated Metastatic Pancreatic Cancer

Print this page 30 December 2019 — AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) today announced that Lynparza® (olaparib) has been approved in the US for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose… Read More »

Cavvy Savvy: Dentistry: Not Just a Treatment – Tri-State Livestock News

A severe overbite can prevent effective grazing and if left unchecked can cause severe damage. Dentistry across all mammalian species has progressed by leaps and bounds over the past 30 years for a multitude of reasons. Today, though, I’m going to concentrate on equine dentistry. Because the teeth in a horse’s mouth continually erupt the… Read More »

FDA Approves Dayvigo (lemborexant) for the Treatment of Insomnia in Adult Patients

FDA Approves Dayvigo (lemborexant) for the Treatment of Insomnia in Adult Patients Print this page December 23, 2019 — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) today announced that the U.S. Food and Drug Administration (FDA) approved the new drug application for its in-house discovered and developed orexin receptor antagonist Dayvigo (lemborexant). Dayvigo… Read More »

FDA Approves Zulresso (brexanolone) for the Treatment of Postpartum Depression

FDA Approves Zulresso (brexanolone) for the Treatment of Postpartum Depression Print this page March 19, 2019 — The U.S. Food and Drug Administration today approved Zulresso (brexanolone) injection for intravenous (IV) use for the treatment of postpartum depression (PPD) in adult women. This is the first drug approved by the FDA specifically for PPD. “Postpartum depression… Read More »